BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rimola J, Díaz-González Á, Darnell A, Varela M, Pons F, Hernandez-Guerra M, Delgado M, Castroagudin J, Matilla A, Sangro B, Rodriguez de Lope C, Sala M, Gonzalez C, Huertas C, Minguez B, Ayuso C, Bruix J, Reig M. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. Hepatology 2018;67:612-22. [PMID: 28898447 DOI: 10.1002/hep.29515] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188382. [PMID: 32522600 DOI: 10.1016/j.bbcan.2020.188382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 da Fonseca LG, Reig M, Bruix J. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. Clin Liver Dis 2020;24:719-37. [PMID: 33012455 DOI: 10.1016/j.cld.2020.07.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
3 Pinato DJ, Marron TU, Mishra-Kalyani PS, Gong Y, Wei G, Szafron D, Sharon E, Saeed A, Jun T, Dharmapuri S, Naqash AR, Peeraphatdit T, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, D'Alessio A, Kaseb AO, Huang YH, Ang C, Schneider J, Pillai A, Rimassa L, Goldberg KB, Pazdur R, Theoret M, Lemery S, Fashoyin-Aje ', Cortellini A, Pelosof L. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer 2021;157:140-52. [PMID: 34508996 DOI: 10.1016/j.ejca.2021.08.020] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Vogel A, Saborowski A. Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma. Cancer Treat Rev. 2020;82:101946. [PMID: 31830641 DOI: 10.1016/j.ctrv.2019.101946] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 13.0] [Reference Citation Analysis]
5 Chien SC, Chen CY, Cheng PN, Liu YS, Cheng HC, Chuang CH, Chang TT, Chiu HC, Lin YJ, Chiu YC. Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study. Liver Cancer 2019;8:186-202. [PMID: 31192155 DOI: 10.1159/000489790] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
6 Raoul JL, Frenel JS, Raimbourg J, Gilabert M. Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. Hepat Oncol 2019;6:HEP11. [PMID: 31244990 DOI: 10.2217/hep-2019-0001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
7 Grothey A, Blay J, Pavlakis N, Yoshino T, Bruix J. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treatment Reviews 2020;86:101993. [DOI: 10.1016/j.ctrv.2020.101993] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
8 Gan G, Shi Z, Shangguan C, Zhang J, Yuan Y, Chen L, Liu W, Li B, Meng S, Xiong W, Mi J. The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases. Theranostics 2021;11:6006-18. [PMID: 33897895 DOI: 10.7150/thno.59841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Marquardt JU, Saborowski A, Czauderna C, Vogel A. The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies. Target Oncol. 2019;14:115-123. [PMID: 30805831 DOI: 10.1007/s11523-019-00624-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
10 Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev. 2018;68:16-24. [PMID: 29783126 DOI: 10.1016/j.ctrv.2018.05.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
11 Lin CC, Hsu CW, Chen YC, Chang ML, Liang KH, Lai MW, Lin CL, Chien RN, Lin KH, Yeh CT. A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy. Pharmacogenomics J 2020;20:57-68. [PMID: 31611591 DOI: 10.1038/s41397-019-0106-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Díaz-gonzález Á, Sanduzzi-zamparelli M, Sapena V, Torres F, Llarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2019;49:482-91. [DOI: 10.1111/apt.15088] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
13 Tutusaus A, Stefanovic M, Boix L, Cucarull B, Zamora A, Blasco L, de Frutos PG, Reig M, Fernandez-Checa JC, Marí M, Colell A, Bruix J, Morales A. Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. Oncotarget 2018;9:16701-17. [PMID: 29682179 DOI: 10.18632/oncotarget.24673] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
14 Nunes G, Fonseca C, Patita M, Aleixo MJ, Ramalho M, Fonseca J. Diffuse advanced hepatocellular carcinoma after HCV eradication in an HIV-infected patient: A unique complete response to sorafenib. Turk J Gastroenterol 2020;31:184-6. [PMID: 32141829 DOI: 10.5152/tjg.2020.181044] [Reference Citation Analysis]
15 Zhang X, Wang F, Gu G, Wu Q. High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients. J Oncol 2021;2021:9938207. [PMID: 34194500 DOI: 10.1155/2021/9938207] [Reference Citation Analysis]
16 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol 2018; 10(9): 571-584 [PMID: 30310535 DOI: 10.4254/wjh.v10.i9.571] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
17 Pinter M, Sieghart W. Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure? Memo 2018;11:185-92. [PMID: 30220924 DOI: 10.1007/s12254-018-0431-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Labeur TA, Hofsink Q, Takkenberg RB, van Delden OM, Mathôt RAA, Schinner R, Malfertheiner P, Amthauer H, Schütte K, Basu B, Kuhl C, Mayerle J, Ricke J, Klümpen HJ. The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial. Acta Oncol 2020;59:1028-35. [PMID: 32366155 DOI: 10.1080/0284186X.2020.1759826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Riaño I, Martín L, Varela M, Serrano T, Núñez O, Mínguez B, Rodrigues PM, Perugorria MJ, Banales JM, Arenas JI. Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial). Cancers (Basel) 2020;12:E1900. [PMID: 32674461 DOI: 10.3390/cancers12071900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Du Pont V, Plemper RK, Schnell MJ. Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses. Curr Opin Virol 2019;35:1-13. [PMID: 30753961 DOI: 10.1016/j.coviro.2018.12.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
21 Corominas J, Sapena V, Sanduzzi-Zamparelli M, Millán C, Samper E, Llarch N, Iserte G, Torres F, Da Fonseca LG, Muñoz-Martínez S, Forner A, Bruix J, Boix L, Reig M. Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:426. [PMID: 33498698 DOI: 10.3390/cancers13030426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Huang K, Lee P, Chao Y, Su C, Lee I, Lan K, Chu C, Hung Y, Chen S, Hou M, Huang Y. Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:175883592210994. [DOI: 10.1177/17588359221099401] [Reference Citation Analysis]
23 Wang E, Xia D, Bai W, Wang Z, Wang Q, Liu L, Wang W, Yuan J, Li X, Chen H, Lv Y, Niu J, He C, Guo W, Yin Z, Luo B, Han N, Wang Z, Yu T, Yuan X, Li K, Tie J, Li C, Cai H, Xia J, Fan D, Han G. Hand-foot-skin reaction of grade ≥ 2 within sixty days as the optimal clinical marker best help predict survival in sorafenib therapy for HCC. Invest New Drugs 2019;37:401-14. [PMID: 30019101 DOI: 10.1007/s10637-018-0640-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Raoul JL, Adhoute X, Penaranda G, Perrier H, Castellani P, Oules V, Bourlière M. Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis. Liver Cancer 2019;8:457-67. [PMID: 31799203 DOI: 10.1159/000497161] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
25 Colombatto P, Demirtas CO, Ricco G, Civitano L, Boraschi P, Scalise P, Cavallone D, Oliveri F, Romagnoli V, Bleve P, Coco B, Salvati A, Urbani L, Bonino F, Brunetto MR. Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib. Cancers (Basel) 2021;13:2064. [PMID: 33922938 DOI: 10.3390/cancers13092064] [Reference Citation Analysis]
26 Tovoli F, Negrini G, Benevento F, Faggiano C, Goio E, Granito A. Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. Hepat Oncol 2018;5:HEP01. [PMID: 30302192 DOI: 10.2217/hep-2017-0020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
27 Lee SK, Jang JW, Nam H, Sung PS, Kim HY, Kwon JH, Lee SW, Song DS, Kim CW, Song MJ, Choi HJ, You YK, Bae SH, Choi JY, Yoon SK. Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation. Hepatol Int 2021;15:137-45. [PMID: 33496932 DOI: 10.1007/s12072-020-10131-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Xie H, Tian S, Yu H, Yang X, Liu J, Wang H, Feng F, Guo Z. A new apatinib microcrystal formulation enhances the effect of radiofrequency ablation treatment on hepatocellular carcinoma. Onco Targets Ther 2018;11:3257-65. [PMID: 29910621 DOI: 10.2147/OTT.S165000] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
29 Ko KL, Mak LY, Cheung KS, Yuen MF. Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Res 2020;9:F1000 Faculty Rev-620. [PMID: 32595940 DOI: 10.12688/f1000research.24543.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
30 Yu T, Cao J, Alaa Eddine M, Moustafa M, Mock A, Erkut C, Abdollahi A, Warta R, Unterberg A, Herold-Mende C, Jungwirth G. Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo. Cancers (Basel) 2021;13:5898. [PMID: 34885009 DOI: 10.3390/cancers13235898] [Reference Citation Analysis]
31 Escudier B, Worden F, Kudo M. Sorafenib: key lessons from over 10 years of experience. Expert Rev Anticancer Ther. 2019;19:177-189. [PMID: 30575405 DOI: 10.1080/14737140.2019.1559058] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
32 Zou Y, Sun H, Guo Y, Shi Y, Jiang Z, Huang J, Li L, Jiang F, Lin Z, Wu J, Zhou R, Liu Y, Ao L. Integrative Pan-Cancer Analysis Reveals Decreased Melatonergic Gene Expression in Carcinogenesis and RORA as a Prognostic Marker for Hepatocellular Carcinoma. Front Oncol 2021;11:643983. [PMID: 33842355 DOI: 10.3389/fonc.2021.643983] [Reference Citation Analysis]
33 Qadan M, Kothary N, Sangro B, Palta M. The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Am Soc Clin Oncol Educ Book 2020;40:1-8. [PMID: 32213090 DOI: 10.1200/EDBK_280811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Rodríguez-Hernández MA, de la Cruz-Ojeda P, López-Grueso MJ, Navarro-Villarán E, Requejo-Aguilar R, Castejón-Vega B, Negrete M, Gallego P, Vega-Ochoa Á, Victor VM, Cordero MD, Del Campo JA, Bárcena JA, Padilla CA, Muntané J. Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer. Redox Biol 2020;36:101510. [PMID: 32593127 DOI: 10.1016/j.redox.2020.101510] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]